Spark Therapeutics (NASDAQ:ONCE) Downgrade
In a research note made public on 12 December, equity research analysts at Leerink Partners’s equity research division decreased Spark Therapeutics (NASDAQ:ONCE)’s stock rating from Outperform to Mkt Perform.
Out of 9 analysts covering Spark Therapeutics, 5 rate it a Buy, 3 indicate a Hold while 1 suggest a Sell. The highest target is $94 and the lowest is $29 according to Thomson/First Call. The 12-month mean target is $58.44, which means downside potential of 21.14% over the current price.
Rock Springs Capital Management Lp had the largest stake with ownership of 625,000 shares as of q2 2015 for 2.35% of the equity exposure. Brookside Capital Management Llc is another bullish institutional investor who is owning 367,314 shares of Spark Therapeutics or 1.43% of their equity exposure. Also, Ecor1 Capital Llc have 1.26% of their equity exposure invested in the company for 68,600 shares. The New York-based fund Deerfield Management Co revealed it had acquired a stake worth about 1.03% of the institutional investor’s stock portfolio in Spark Therapeutics. The New York-based fund Baker Bros. Advisors Lp is also positive about the stock, possessing 368,000 shares or 0.72% of their equity exposure.
Spark Therapeutics (NASDAQ:ONCE) Profile
Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.
Spark Therapeutics (NASDAQ:ONCE) traded up 0.11% on 12 December, hitting $74.11. A total of 177,872 shares of the company’s stock traded hands. This is down from average of 518,672 shares. Spark Therapeutics has a 52 week low of $47.03 and a 52 week high of $91.75. The company has a market cap of $2.74B and a P/E ratio of 0.
Get the latest Spark Therapeutics (NASDAQ:ONCE) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Leerink Partners Downgrades Spark Therapeutics (NASDAQ:ONCE) Rating to Mkt Perform from Outperform appeared first on Octafinance.